Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sagimet Biosciences Inc.

3.74
+0.23006.55%
Post-market: 3.780.0400+1.07%18:53 EDT
Volume:281.00K
Turnover:1.04M
Market Cap:120.41M
PE:-2.90
High:3.80
Open:3.55
Low:3.50
Close:3.51
Loading ...

Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position

TIPRANKS
·
14 Mar

Sagimet Biosciences Price Target Announced at $32.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom

TIPRANKS
·
13 Mar

Sagimet Biosciences Advances MASH Treatment with New Trials

TIPRANKS
·
13 Mar

Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Mar

Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567

TIPRANKS
·
12 Mar

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials

MT Newswires Live
·
11 Mar

Sagimet Biosciences receives FDA nod to begin testing its therapy for acne

Reuters
·
11 Mar

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

GlobeNewswire
·
11 Mar

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?

Insider Monkey
·
25 Feb

BRIEF-Sagimet Biosciences Announces Oral Presentation At The Mash Pathogenesis And Therapeutic Approaches Keystone Symposium

Reuters
·
19 Feb

Sagimet Biosciences Announces Oral Presentation at the Mash Pathogenesis and Therapeutic Approaches Keystone Symposium

THOMSON REUTERS
·
19 Feb

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

GlobeNewswire
·
19 Feb

Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity

TIPRANKS
·
04 Feb

BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating

Reuters
·
27 Jan

Sagimet Biosciences Inc : Jonestrading Initiates Coverage With Buy Rating; Price Target $42

THOMSON REUTERS
·
27 Jan